Search

Peter Lobo, MD Lab

PRIMARY APPOINTMENT


Professor of Medicine, Medicine: Nephrology

Contact:

UVA Division of Nephrology
PO Box 800133
Charlottesville, VA 22908
Telephone: 434-924-5125
Email: pil@hscmail.mcc.virginia.edu

EDUCATION AND TRAINING

  • Fellowship, Nephrology, Immunology, Transplantation, University of Virginia
  • MD, Makerere University
  • Residency, Makerere University

RESEARCH AREAS

Basic Transplant Immunology; Role of Naturally occurring IgM antibodies in Acute Kidney Injury and transplant rejection.

CURRENT LABORATORY MEMBERS

Lab Team Images

  • two lab members

    Peter Lobo, MD and Kailo Schlegel

  • two lab members

    Zhongmin Du and Kailo Schlegel

  • Lab Member working in lab

    Zhongmin Du

  • Lab member

    Peter Lobo, MD

  • two lab members

    Peter Lobo, MD and Mark Okusa, MD

  • Group picture of the nephrology lab

    Nephrology Lab Team

  • Lab Member working in lab

    Sylvia Cechova, PhD

  • Lab Member

    Kailo Schlegel, Zhongmin Du, Nataliya Skrypnyk, and Peter Lobo

  • lab member working in the lab

    Sylvia Cechova, PhD

RESEARCH SUMMARY

My primary research investigates the role of naturally occurring IgM autoantibodies that bind to receptors on inflammatory and endothelial cells. Thus far, we have shown that these antibodies regulate inflammatory cell functions and downregulate the inflammatory response that occurs after acute ischemic injury to the kidney and after transplantation (i.e. rejection). A subset of normal individuals and patients awaiting transplantation (i.e. kidney, heart) have high levels of these natural antibodies. We and others have noted a strong association between the presence of elevated IgM anti-leukocyte natural antibodies and protection from rejection.

Currently, our primary research efforts are focused on 1) studying the mechanism by which IgM downregulates the inflammatory response; 2) determining if there is a role of IgM in inducing transplant tolerance, thus decreasing the use of immunosuppressive agents; and 3) evaluating strategies (e.g. vaccines) to increase levels of such antibodies, especially in patients awaiting transplantation. Other clinical studies aim to determine if there is an association between levels of such antibodies and the severity of renal failure (e.g. after cardiac surgery) and severity of glomerular inflammation (e.g. in SLE or IgA nephropathy).

My clinical research involves transplant immunobiology, primarily focusing on B cell regulation, alloantibodies, and desensitizing patients with donor-specific antibodies.